News UK haemophilia A patients get once-weekly treatment option A long-acting Factor VIII replacement therapy for haemophilia A from Sobi and Sanofi has been recommended for use by the NHS.
News Sobi gets EU okay for long-acting haemophilia A drug The European Commission has approved Sobi’s long-acting factor VIII replacement therapy Altuvoct for the treatment of haemophilia A in the EU, with a broad label that spans all ages and any
News Appeal finds NICE must reconsider Alzheimer's drugs Lilly and Eisai's bid to secure NHS coverage of their Alzheimer's therapies has entered a new phase, after an appeal of last year's rejection by NICE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
